-

Aqemia to Participate in Jefferies European Disruptive Tech Conference

original Maximilien_Levesque_CEO_Aqemia.

Maximilien_Levesque_CEO_Aqemia.

LONDON--(BUSINESS WIRE)--Aqemia, a pioneering TechBio company leveraging advanced physics and generative AI for drug discovery, announced that its CEO and co-founder, Maximilien Levesque, will participate in the European Disruptive Tech Conference hosted by Jefferies in London on October 9, 2025.

Within the TechBio track, Dr. Levesque will join the HealthTech Panel, scheduled for 13:00 BST.

About Aqemia

Aqemia is a drug invention company dedicated to creating novel molecules to address unmet medical needs. Its proprietary QEMI platform combines more than 12 years of physics-based research with state-of-the-art generative AI, enabling the launch of preclinical programs without relying on experimental data and accelerating discovery from day one. Aqemia’s portfolio spans oncology, immunology, neurology, and cardiology, and includes both wholly owned programs and partnered programs with leading pharmaceutical companies, such as a multi-year, $150M strategic collaboration with Sanofi. The company’s most advanced preclinical programs are currently undergoing in vivo optimization. Headquartered in Paris with an office in London, Aqemia has raised over $100 million since its inception.

Contacts

Press Contact
Orianne Bornand - Head of Communications
+33 6 10 04 32 80 I orianne.bornand@aqemia.com

Industry:

Aqemia

Release Versions
English

Contacts

Press Contact
Orianne Bornand - Head of Communications
+33 6 10 04 32 80 I orianne.bornand@aqemia.com

More News From Aqemia

Aqemia to Participate in the Jefferies Global Healthcare Conference 2025

LONDON--(BUSINESS WIRE)--Aqemia, a pioneering TechBio company combining generative AI and quantum-inspired physics to invent drugs, announces that Maximilien Levesque, CEO and co-founder, and Théa Vu-Bignand, VP Finance, will attend the Jefferies Global Healthcare Conference, taking place in London from November 17 – 20, 2025. With its physics-based generative AI platform for therapeutic molecule invention, QEMI, Aqemia can design novel drug candidates in a repeatable, frugal, and scalable way,...

Aqemia Advances Epitranscriptomics Programs and Expands into Small-Molecule RNA Targeting with $7.4 Million Grant

PARIS & LONDON--(BUSINESS WIRE)--Aqemia announces it is broadening and accelerating its computational platform to target RNAs using its physics-enabled generative AI engine. Building on successes in epitranscriptomics, Aqemia aims to develop novel small-molecule drugs against this emerging and promising class of therapeutic targets. In parallel with advancing RNA-focused initiatives, the company continues to drive innovation in its broader pipeline, including protein-targeting programs. New Fun...

AQEMIA Hits $100 Million Funding Milestone, Paving Way to Clinical Trials and Global Expansion Starting with London, UK

PARIS & LONDON--(BUSINESS WIRE)--AQEMIA, a pioneering techbio that teaches atomic scale physics to a generative AI to invent innovative medicines, announces two major milestones: $100 million in cumulative funding and the beginning of a global expansion starting with London (United Kingdom). The new $38 million funding round, led by new investor Cathay Innovation, brings total funds raised since inception to over $100 million. This round, coming less than a year after the previous one, follows...
Back to Newsroom